# Derazantinib and Atezolizumab in Patients With Urothelial Cancer

> **NCT04045613** · PHASE1,PHASE2 · COMPLETED · sponsor: **Basilea Pharmaceutica** · enrollment: 95 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Derazantinib 300 mg once daily monotherapy
- **DRUG:** Derazantinib 200 mg once daily + atezolizumab 1200 mg
- **DRUG:** Derazantinib 300 mg once daily+ atezolizumab 1200 mg
- **DRUG:** Derazantinib 200 mg twice daily + atezolizumab 1200 mg
- **DRUG:** Derazantinib 300 mg once daily monotherapy (QD)
- **DRUG:** Derazantinib 300 mg once daily + atezolizumab 1200 mg
- **DRUG:** Derazantinib 200 mg twice daily monotherapy

## Key facts

- **NCT ID:** NCT04045613
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-02
- **Primary completion:** 2022-10-04
- **Final completion:** 2022-10-04
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2023-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04045613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04045613, "Derazantinib and Atezolizumab in Patients With Urothelial Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04045613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*